PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements

A subset of patients with EGFR mutations or ALK rearrangements had a PD-L1 TPS of ≥50%. Prospective studies are thus warranted to examine the efficacy of PD-1/PD-L1 inhibitors in such patients.